Solutions Throughout the Entire Diagnostics Continuum

Advancing laboratory diagnostics

Every test tells a story—and behind every result is a patient, a family, and a decision that matters. At Thermo Fisher Scientific, we’re proud to support your lab with differentiated diagnostics that drive clinical confidence, streamline workflows, and help elevate patient care across the diagnostic continuum.

Accurate results start long before analysis. Our pre-analytical solutions ensure specimen integrity and efficiency from the moment a sample is collected.

Bridge innovation to implementation with tools for biomarker discovery, assay development, and translational research.

From immunoassays to molecular testing, our platforms deliver accurate, fast answers that drive confident decisions.

Reduce manual steps, errors, and downtime with automated systems tailored for the diagnostic environment.

Turn data into decisions with LIS integrations, analytics platforms, and real-time quality control.


From sample to insight: advancing every stage of diagnostics

We understand that laboratories like yours play a crucial role in advancing diagnostic excellence and influencing patient outcomes—and we’re here to support you. At Thermo Fisher, we take pride in leading the way in differentiated diagnostics.


For earlier detection & diagnosis

Transforming preeclampsia care with PreClaraTM biomarkers

Enhance prenatal care with the PreClara Ratio (sFlt-1/PIGF) biomarker test, a clinically proven tool for the risk assessment and clinical management of preeclampsia. This innovative test supports more accurate triage and timely intervention—helping healthcare providers differentiate between patients at high risk of developing severe disease and those who can be safely monitored.

Precision starts here: Genomic profile in as little as 24 hours with Oncomine Dx Express Test

This automated, true end-to-end solution* from a single supplier and requiring only 20 minutes of hands-on time—can be implemented in a broad spectrum of clinical labs, even without next-generation sequencing (NGS) expertise. Ion Torrent Oncomine Reporter Dx reporting software provides biomarker results matched to approved therapies, guidelines, clinical trials, and peer-reviewed literature to aid clinicians in therapy management of cancer patients.

  • Content covers gene targets recommended by professional guidelines for multiple solid tumors
  • Requires only 10 ng of DNA and RNA extracted from as little as two 5-micron FFPE slides, results can be generated from limited tissue and small biopsies
  • Compatible with Genexus Dx system for sample-to-answer in a single day

For reliable monitoring & lab confidence

EXENT® System from the Binding Site

The EXENT System utilizes mass spectrometry technology designed to provide clear and precise assessment of disease in patients with multiple myeloma and related conditions.

  • Designed to specifically address workflow and interpretation challenges faced by clinical laboratories.
  • Empower clinicians to effectively assess patient disease with a simple serum test.
  • Part of Thermo Fisher's commitment to hematologic innovation using MALDI-ToF mass spectrometry technology.

One Lambda HLA Typing and Antibody Detection Solutions for Improved Transplant Outcomes

Enhance donor-recipient compatibility analysis with Thermo Fisher Scientific's One Lambda HLA assays. Designed for accuracy and reliability, these tools support critical decisions in solid organ and stem cell transplantation.

  • Workflow Solutions: Integrated assays, instruments, and software that streamline testing evaluations. Simplified protocols help reduce hands-on time and deliver faster results.
  • Flexible Platforms: Multiple options from PCR-based typing to NGS, plus industry-leading antibody detection products to meet diverse laboratory requirements.
  • Integrated Analysis: Powerful software tools that simplify data interpretation, enhancing laboratory efficiency and supporting your research.

For operational efficiency & readiness

Clarity you can trust: Accurate specific IgE testing with ImmunoCAP assays

Deliver confidence in the aid of allergy diagnosis with trusted in vitro specific IgE testing.1  ImmunoCAP assays are designed to provide reproducible, quantitative results across a broad allergen menu—from food and respiratory to environmental and occupational triggers.

  • Supported by more than 4,000 peer-reviewed publications2
  • Reduce diagnostic uncertainty and enhance treatment planning
  • High sensitivity and specificity detection
  • Analyzed on our automated Phadia Laboratory Systems

Lab-ready. Every day. Powered by Fisher Healthcare.

Simplify your diagnostic operations with reliable access to critical lab supplies, consumables, and point-of-care products from a trusted partner. Fisher Healthcare ensures availability, scale, and logistics that labs depend on.

  • Distribution across hospitals, reference labs, and public health networks
  • Backed by Thermo Fisher’s global logistics infrastructure
  • One-stop shop with personalized procurement and support

Real lives, real impact

See how diagnostic insights changed the course of care.

Maddie's story: A personalized therapy that contributed to saving her life

Diagnosed with cancer at just four months old, Maddie endured multiple rounds of chemotherapy. When her cancer returned and resisted treatment, doctors turned to Thermo Fisher’s next-generation sequencing (NGS) technology. This advanced testing identified a targeted therapy that helped in the treatment of her cancer, giving Maddie a second chance at life.

Yolando's story: Early detection for a healthier pregnancy

Facing potential complications during pregnancy, Yolando benefited from Thermo Fisher’s FDA-cleared preeclampsia screening test. This innovative blood test assessed her risk for developing severe preeclampsia, allowing her healthcare team to take proactive measures to safeguard the safety of both mother and baby.

References

  1. Crameri R. Chapter 3a: In Vitro Allergy Diagnosis—Allergen Specific IgE. In: Adkins CA, Agache I, eds. Global Atlas of Allergy. European Academy of Allergy and Clinical Immunology; 2014;166-167.
  2. Ansotegui IJ, et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organ J. 2020;13(2):100080.

*Review with oncology slides.

† For In Vitro Diagnostic Use. CE-IVD according to IVDD. Not available in all countries including the United States.

‡The EXENT® System combines EXENT® Analyzer with the Immunoglobulin Isotypes (GAM) for the EXENT® Analyzer. EXENT is a registered trademark of The Binding Site Group Limited (Birmingham, UK) in certain countries. Product availability is subject to country specific regulatory requirements. The EXENT Analyzer and Immunoglobulin Isotypes (GAM) for EXENT Analyzer are only commercially available in Australia, New Zealand, United Kingdom, Switzerland and the EEA. Product availability is subject to country specific regulatory requirements. Contact your local representative for availability in your country. The products are not commercially available in the USA or China, future commercial availability cannot be guaranteed.

Intended use of the products mentioned on this page vary. For specific intended use statements please refer to the product label.